Lantern Pharma Raises $4.4 Million to Advance AI-Driven Cancer Therapies

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage precision oncology company headquartered in Dallas, Texas, has announced the closing of a registered direct offering that raised approximately $4.4 million in gross proceeds. The offering involved the sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share. In a concurrent private placement, the company also issued unregistered warrants to purchase up to 2,135,923 additional shares at an exercise price of $2.27 per share, which could generate up to approximately $4.85 million in additional gross proceeds if fully exercised.

The capital raise provides Lantern Pharma with additional financial flexibility to advance its oncology programs and expand the reach of its AI capabilities. The company continues to leverage its proprietary RADR® platform, which uses artificial intelligence and machine learning to transform the development of cancer therapies. Lantern Pharma's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.

Beyond its pipeline, Lantern Pharma has introduced withZeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research platform for the global biomedical and drug development community. This platform represents a new revenue stream for the company, which operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company's efforts highlight the growing intersection of artificial intelligence and biotechnology, positioning Texas as a hub for innovative cancer research.

The implications of this offering extend beyond Lantern Pharma's immediate funding needs. By raising capital through a direct offering and warrants, the company signals confidence in its pipeline and AI platform to investors. The potential for up to $4.85 million in additional proceeds from warrant exercises could further accelerate development timelines for LP-184, LP-284, and LP-300. For the industry, Lantern Pharma's approach demonstrates how AI can streamline drug development, potentially reducing costs and time to market for new cancer therapies. For readers in Texas, the company's growth underscores the state's role in fostering life sciences innovation. Investors can find the latest news and updates relating to LTRN in the company's newsroom at https://ibn.fm/LTRN. For more information on the press release, visit https://ibn.fm/Oh6jI.